Stay current with the latest news on Blood Cancer United research programs, FDA approvals, research grants and awards, the Therapy Acceleration Program, Beat AML and other clinical research programs, and more.
Research
Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
BERKELEY, Calif., April 04, 2023 - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company,…
News
FDA Approves New Formulation of Important Childhood Leukemia Drug
The U.S. Food and Drug Administration yesterday approved nelarabine injection, a critical treatment for T-cell acute lymphoblastic leukemia (T-ALL), a…
News
FDA Approves New Type of BTK Inhibitor to Treat Mantle Cell Lymphoma
The U.S. Food and Drug Administration today approved pirtobrutinib (Jaypirca™), the first non-covalent, reversable BTK inhibitor for the treatment of …
News
FDA Approves the First-in-Class Bispecific Antibody for Treatment of Follicular Lymphoma
“This new treatment has the potential to help patients with this hard-to-treat cancer achieve remission,” says LLS Chief Scientific Officer Dr. Lee Gr…
News
FDA Approves New Targeted Treatment Option for Certain Forms of Acute Myeloid Leukemia in Adults
The U.S. Food and Drug Administration (FDA) granted approval yesterday to olutasidenib (Rezlidhia™) for the treatment of adults with acute myeloid leu…
Research
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
BERKELEY, Calif., Nov. 29, 2022 - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, …
News
LLS Applauds FDA Approval of New Treatment Option for Pediatric Patients with Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) yesterday approved brentuximab vedotin (Adcetris®) in combination with standard dose-intensive chemotherap…
News
FDA Broadens Treatment Options for Relapsed/Refractory Multiple Myeloma
The Food and Drug Administration (FDA) has approved a new treatment, teclistamab (Tecvayli), for adults with multiple myeloma that has returned or con…
News
FDA Approves New Treatment for Children and Young Adults with Chronic Graft versus Host Disease
This week marked another milestone for the treatment of graft versus host disease in children. The U.S. Food and Drug Administration (FDA) approved ib…
Research
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
SANTA MONICA, Calif. April 1, 2022 - Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Y…
News
FDA Approves Immunotherapy for Aggressive Form of Follicular Lymphoma
The U.S. Food and Drug Administration (FDA) has approved CAR T-immunotherapy tisagenlecleucel (Kymriah®) for patients with follicular lymphoma (FL) wh…
